Article Details
Retrieved on: 2024-11-28 16:06:21
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the interstitial lung disease treatment market, emphasizing market research and growth due to rising lung disorders, including idiopathic pulmonary fibrosis. It highlights drug developments by companies like Boehringer Ingelheim and Roche, mentioning key treatments such as nintedanib and pirfenidone.
Article found on: www.vantagemarketresearch.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here